Molecule
Sodium acetate is an osmotic laxative indicated as a source of sodium, for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake. MedsAcross supplies Sodium acetate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Sodium Acetate Injection, USP 40 mEq is indicated as a source of sodium, for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions.
Source: US FDA prescribing information
Sodium Acetate Injection, USP 40 mEq is administered intravenously only after dilution in a larger volume of fluid. The dose and rate of administration are dependent upon the individual needs of the patient. Serum sodium should be monitored as a guide to dosage. Using aseptic technique, all or part of the contents of one or more vials may be added to other intravenous fluids to provide any desired number of milliequivalents (mEq) of sodium (Na + ) with an equal number of acetate (CH 3 COO - ). Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. See PRECAUTIONS.
Source: US FDA prescribing information
Sodium Acetate Injection, USP 40 mEq is contraindicated in patients with hypernatremia or fluid retention.
Source: US FDA prescribing information
Sodium Acetate Injection, USP 40 mEq must be diluted before use. To avoid sodium overload and water retention, infuse sodium-containing solutions slowly. Solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention. In patients with diminished renal function, administration of solutions containing sodium ions may result in sodium retention. Solutions containing acetate ions should be used with great care in patients with metabolic or respiratory alkalosis. Acetate should be administered with great care in those conditions in which there is an increased level or an impaired utilization of this ion, such as severe hepatic insufficiency.
Source: US FDA prescribing information
Sodium overload can occur with intravenous infusion of excessive amounts of sodium-containing solutions. See WARNINGS and PRECAUTIONS.
Source: US FDA prescribing information
Store at 20 to 25°C (68 to 77°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
6 presentations of Sodium acetate, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Sodium acetate 8200 mg/50 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Sodium acetate 16400 mg/100 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Sodium acetate 3280 mg/20 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Sodium acetate 200 mEq/100 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Sodium acetate 4 mEq/100 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Sodium acetate 400 mEq/100 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 4 May 1983 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 6 presentations of Sodium acetate and sources them for licensed hospitals, importers and physicians against valid import documents.
Yes. The US FDA first approved Sodium acetate on 4 May 1983, according to Drugs@FDA.
No listed presentation of Sodium acetate is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Sodium acetate is classified under ATC code B05XA08 (Sodium acetate).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.